240 results on '"Hoffe, S"'
Search Results
2. Survival in locally advanced pancreatic cancer after chemotherapy and radiation therapy
3. Toward Burnout Prevention: Can One Short Virtual Reality Relaxation and Mindfulness Training Session for Staff and Patients Decrease Stress and Improve Subjective Sense of Wellbeing?
4. Pancreas Cancer Learning Health Network Established to Share Best Practice Across 14 Centers and Improve Patient Outcomes
5. Adrenal Stereotactic Body Radiation Therapy: Do Dosimetric Factors Predict for Grade 2+ Lymphopenia?
6. Borderline Resectable Pancreatic Cancer: Impact on Neoadjuvant Response Post Integration of MRI Guided Adaptive Radiation Therapy
7. Outcomes of Cytoreductive Stereotactic Body Radiotherapy (SBRT) in Patients with Oligometastatic or Oligoprogressive Dominant Lung Metastases from Colorectal Primary
8. MO-0959 A novel multi-task hybrid deep neural network (DNN) predicts tumor progression during MRgRT
9. Review of current best practice and priorities for research in radiation oncology for elderly patients with cancer: the International Society of Geriatric Oncology (SIOG) task force
10. Re-planning for Compensator-Based IMRT with Original Compensators
11. Multi-Institutional Experience of MR-Guided Stereotactic Body Radiation Therapy for Adrenal Gland Metastases
12. Leading Change: Perceptions of Current Radiation Oncology Residents and Attending Physicians about the State of the Didactic Curriculum
13. Primary Tumor-Directed MRI-Guided Ablative Radiation Therapy for Patients with Metastatic Pancreatic Adenocarcinoma
14. Abstract No. 4 ▪ ABSTRACT OF THE YEAR Radioembolization with yttrium-90 glass microspheres as first-line treatment for unresectable intrahepatic cholangiocarcinoma: a prospective phase 2 clinical trial
15. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer
16. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer
17. Multisequence MRI With Functional Imaging May Improve Pseudoprogression vs. Viable Tumor Determination Following High Dose Adaptive MRgRT in Patients With Pancreatic Adenocarcinoma
18. GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in Combination with GC4711 in the Treatment of Unresectable or Borderline Resectable Nonmetastatic Pancreatic Cancer (PC)
19. Impact of Tumor Dosimetry on Clinical Outcomes after Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma
20. Radiomic Feature Changes in Adrenal Lesions Treated With MR-Guided Stereotactic Body Radiation Therapy
21. Additional file 1 of Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer
22. Abstract No. 160 Unresectable intrahepatic cholangiocarcinoma treated with radiation segmentectomy/lobectomy using Y90-labeled glass microspheres
23. Abstract No. 72 Yttrium-90 radioembolization treatment of patients with liver-dominant metastatic renal cell carcinoma
24. Abstract No. 73 Yttrium-90 radioembolization in liver-dominant metastatic castrate-resistant prostate cancer
25. Abstract No. 5 Correlation between tumor enhancement measured with intraprocedural 4D-CT and tumor response in patients with hepatocellular carcinoma treated with Yttrium-90 radioembolization
26. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC)
27. Analysis of MR Guided SBRT Imaging Data for Quantification of Early Radiotherapy Response Signal in Pancreatic Adenocarcinoma
28. Yttrium-90 Glass Microsphere Transarterial Radioembolization for Patients with Unresectable Liver-Dominant Breast Cancer Metastasis
29. Cost-Effectiveness Threshold of Magnetic Resonance Image-Guided Radiotherapy for Localized Prostate Cancer
30. A Single Institution Experience On High Dose MRI-Guided Stereotactic Body Radiotherapy For Pancreatic Cancer: Early Outcomes, Safety And Feasibility
31. OncoPaC-1: An Open-label, Single-Arm Pilot Study of Phosphorus-32 Microparticles Brachytherapy in Combination with Gemcitabine +/- Nab-Paclitaxel in Unresectable Locally Advanced Pancreatic Cancer
32. A Novel Radiation Oncology Residency Training Leadership Curriculum: Baseline Attitudes of Past and Current Residents
33. Beyond Blind Dose-Escalation: Modeling Precision Genomic-Based Radiation Dose-Response In Rectal Cancer
34. Composite Pretreatment CT and 18F-FDG PET Radiomic-Based Prediction of Pathological Response of Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy
35. Do Health Insurance and Other Psychosocioeconomic Determinants of Health Impact Survival Through Treatment Delays with Stereotactic Body Radiation Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer Patients?
36. Pathologic Outcomes of Systemic Therapy Followed By Stereotactic Body Radiation Therapy for Pancreatic Cancer in a Novel Lateral Decubitus Treatment Position
37. P112: In situ simulation: A team sport?
38. Abstract No. 537 Transarterial yttrium-90 radioembolization treatment of pancreatic cancer patients with liver-dominant metastatic disease
39. Consensus Report From the Miami Liver Proton Therapy Conference
40. Consensus Report From the Miami Liver Proton Therapy Conference
41. Dose escalated neoadjuvant chemoradiotherapy with dose-painting intensity-modulated radiation therapy and improved pathologic complete response in locally advanced esophageal cancer
42. SU-F-T-372: Surface and Peripheral Dose in Compensator-Based FFF Beam IMRT
43. Transradial access for hepatic radioembolization: the Moffitt experience
44. Synchronous Rectal Adenocarcinoma and Splenic Marginal Zone Lymphoma
45. SU-E-J-254: Evaluating the Role of Mid-Treatment and Post-Treatment FDG-PET/CT in Predicting Progression-Free Survival and Distant Metastasis of Anal Cancer Patients Treated with Chemoradiotherapy
46. SU-E-J-270: Repeated 18F-FDG PET/CTs Based Feature Analysis for the Predication of Anal Cancer Recurrence
47. Metabolic Tumor Volume (MTV) Is a Predictor of Survival in Borderline Pancreatic Cancers Treated With Neoadjuvant Therapy
48. Pretreatment Neutrophil-Lymphocyte Ratio (NLR) Does Not Predict Worse Outcomes in Anal Cancer
49. Pretreatment Neutrophil to Lymphocyte Ratio (NLR) Is Prognostic in Resectable Pancreatic Cancer
50. Carboplatin and paclitaxel as first-line treatment of unresectable or metastatic esophageal or gastric cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.